Posted by Michael Wonder on 10 Apr 2025
Lorlatinib for the treatment of patients with advanced ALK positive non-small-cell lung cancer (review of TA909)
9 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of lorlatinib in the NHS in England.
For the time being, lorlatinib should not be used for the treatment of adults with advanced ALK positive non small-cell lung cancer who have not been treated with an ALK inhibitor.
